利用树突状细胞疫苗恢复HER2/neu阳性乳腺癌中的抗肿瘤驱动Th1反应：进展与潜力
Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.
作者信息
De La Cruz Lucy M, Nocera Nadia F, Czerniecki Brian J
机构信息
Department of Endocrine & Oncologic Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL 33617, USA.
出版信息
Immunotherapy. 2016 Oct;8(10):1219-32. doi: 10.2217/imt-2016-0052.
HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 response can predict response to neoadjuvant therapy, risk of recurrence and disease-free survival. Vaccines consisting of HER2-pulsed type I polarized dendritic cells (DC1) administered during ductal carcinoma in situ and early IBC can efficiently correct anti-HER2Th1 response and have clinical impact on the disease. In this review, we will discuss the role of anti-HER2Th1 response in the three phases of immunoediting during HER2 breast cancer development and opportunities for reversing these processes using DC1 vaccines alone or in combination with standard therapies. Correcting the anti-HER2Th1 response may represent an opportunity for improving outcomes and providing a path to eliminate escape variants.
HER2/neu在大多数原位乳腺癌中表达，但在20%-30%的浸润性乳腺癌（IBC）中持续存在。在乳腺肿瘤发生过程中，从良性病变到原位导管癌，抗HER2 CD4阳性Th1（抗HER2Th1）逐渐减少，在IBC中几乎完全丧失。这种抗HER2Th1反应可预测新辅助治疗的反应、复发风险和无病生存期。在原位导管癌和早期IBC期间给予由HER2脉冲I型极化树突状细胞（DC1）组成的疫苗，可有效纠正抗HER2Th1反应，并对疾病产生临床影响。在本综述中，我们将讨论抗HER2Th1反应在HER2乳腺癌发展免疫编辑三个阶段中的作用，以及单独使用DC1疫苗或与标准疗法联合使用来逆转这些过程的机会。纠正抗HER2Th1反应可能是改善预后和提供消除逃逸变体途径的一个机会。
Zotero 插件